Ireland's pharmaceutical associations have brought the EU's allocation of wastewater-treatment costs before the Court of Justice through an Irish court referral. Published in the Official Journal on 7 September 2026, the reference asks whether provisions imposing producer responsibility breach European legal principles, including equal treatment and protection of human health. It records questions for the court, rather than a ruling that the provisions are invalid.1
A market obligation for medicine suppliers
The directive requires member states to introduce extended producer responsibility for covered medicines and cosmetics by 31 December 2028. Producers must collectively finance at least 80% of the relevant advanced treatment and monitoring costs, alongside associated data and administrative costs. This additional treatment removes micropollutants from urban wastewater.2
The French text describes the system as:
Responsabilité élargie des producteurs
Extended producer responsibility.2
The law's rationale is that suppliers should help fund removal of residues associated with their products, limiting the burden on taxpayers and water bills. It applies to products placed on the Union market regardless of whether production occurs inside or outside the EU. Contributions are linked to the quantity and hazardousness of substances, with specified exemptions.2
The legislature expected the overall effect on affordability to be limited, while asking national authorities to consider possible effects on medicine availability. That expectation is contested by the industry organisations involved in the Irish case.2 3
Industry says regulated prices limit adjustment
Medicines for Ireland and Medicines for Europe argue that the scheme places a disproportionate burden on their sector while leaving out other sources of micropollutants. They also dispute the methodology used to allocate costs. These are the associations' claims about the policy, rather than findings that the court has established.3
The associations say generic and biosimilar suppliers cannot readily reformulate active ingredients because of regulatory constraints. They also point to regulated medicine prices and restricted margins, arguing that additional costs could make some products less viable to supply. Their warning concerns future availability; the statement does not establish an observed contraction in Irish factory output caused by the scheme.3
Export figures do not measure the disputed charge
Irish statistics show the scale of the trade at issue. Medical and pharmaceutical exports were worth about €6.0 billion in August 2026, down 6.7% from a year earlier. Imports in the same category rose 44.6% to about €2.5 billion. These are trade values, not a count of medicines produced or an estimate of wastewater compliance costs.4
The statistical release does not attribute those movements to the producer-responsibility scheme. The latest month's figures were provisional and subject to revision, further limiting conclusions about a specific regulatory effect.4
The Irish High Court stayed the domestic proceedings and sought the European ruling before the directive's transposition deadline of 31 July 2027. Its judgment records the state's rejection of the invalidity claim. The next substantive question is how the European court answers the referral, and what that means for Ireland's implementation timetable.5